Participated · Seed · Jul 2026

KelAI offers an autonomous AI research engine that runs idea generation, backtesting, signal validation and live monitoring within a single platform tailored for hedge funds and institutional asset managers. The company operates on an enterprise software model and targets large institutional investors managing significant assets. KelAI reported that its signals have been running with an institutional investor in production since October 2025, moving the platform beyond theory into live alpha. Founder and CEO Jeremie Cohen says the team combines advanced AI with deep investment domain experience drawn from years inside leading hedge funds. Near-term plans include continued product improvement and selective growth of a New York team. The company is focused on building into a category-defining business at the intersection of AI and institutional investing.

Participated · Seed · Jun 2026

Founded in 2025 by Ines Iraki, Johann Diep, and Professor Eric Vibert, Uncovr builds AI systems that analyse surgical and endoscopic video and intraoperative workflow data to generate structured operative records and coding recommendations. The platform produces draft documentation in real time and outputs are reviewed and approved before submission as clinical records. Uncovr says grounding documentation in procedural data can improve clinical accuracy, coding quality, reimbursement integrity, and continuity of care. The company is already deployed with hospitals in the United States and Europe and reports a deployment pipeline that includes more than 400 operating rooms, with thousands of hours of surgical procedures analysed to date. Uncovr intends to use its seed funding to continue product development, expand hospital deployments, and further develop its AI models for documentation and workflow intelligence.

Led · Equity · May 2026

Fakto builds AI agents that ingest the full corpus of supplier contracts, invoices and pricing grids to extract clauses, compare signed terms to billed amounts and flag deviations. The platform operates in two modes: defensive (recovering overbilled amounts) and offensive (unlocking unexploited contractual value such as volume tiers or consolidation opportunities). Fakto targets large enterprises with more than €500M in revenue in sectors with dense contracting (retail, construction, logistics, manufacturing) and already serves three French groups with revenues between €1B and €40B. In a cited pilot over €40M of fuel spend, Fakto identified 2.5% contract deviations within days after ingesting over 30,000 invoices and unstructured price grids, with one supplier showing a systematic 14% deviation. The company sells a SaaS subscription indexed to covered spend and plans to expand to the U.K. in H2 2026 and the U.S. in early 2027, supported by recent funding and planned tech hires.

Led · Seed · May 2026

Elastics develops AI-driven infrastructure that automates research, execution, and portfolio management for trading, with an emphasis on prediction markets. Its platform enables conversational interactions with markets and includes a “Trade with Words” feature that lets users describe positions in plain language for automatic execution. The product is currently in private beta with early access available to selected users. The company was founded by Szymon Pawica, a former Goldman Sachs professional, and mathematician Mateusz Brodowicz. Elastics plans to hire AI and quantitative talent and to expand its product beyond prediction markets as it continues to build infrastructure for automated, AI-driven trading. Financially, the company recently closed a $2M pre-seed round led by Frst with participation from angel investors across AI and crypto.

Participated · Seed · Apr 2026

Helical offers a platform that turns biological foundation model outputs into reproducible, decision-ready in-silico workflows via two main components: the Virtual Lab for biologists and translational scientists, and the Model Factory for machine learning engineers and data scientists. Its platform integrates computational predictions with biological validation, enabling shared data, models, and results to facilitate collaboration across traditionally siloed teams. The company reports working with several top-20 global pharmaceutical companies and supporting reductions in discovery timelines across target identification, biomarker discovery, and therapeutic design. Helical was founded in early 2024 by Rick Schneider, Maxime Allard, and Mathieu Klop. Financially, it has just completed a $10 million seed round to expand deployments and enhance the platform’s evidence layer.